CardiAsk tablets p / o 50mg, No. 30

• Prevention of acute myocardial infarction in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) and repeated myocardial infarction;

• Unstable angina

• Prevention of stroke (including in patients with transient cerebrovascular accident);

• Prevention of transient disorders of cerebral circulation;

• Prevention of thromboembolism after surgery and invasive interventions on the vessels (for example, coronary artery bypass grafting, endarterectomy of the carotid arteries, arteriovenous bypass grafting, angioplasty of the carotid arteries);

• Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (for example, with prolonged immobilization as a result of major surgery).

CardiASK should be taken orally, before meals, with plenty of fluids.
CardiASK is intended for long-term use. The duration of therapy is determined by the attending physician.
Prophylaxis for suspected acute myocardial infarction 100-200 mg / day or 300 mg every other day (the first tablet must be chewed for faster absorption).
Prevention of new-onset acute myocardial infarction in the presence of risk factors 100 mg per day or 300 mg every other day.
Prevention of recurrent myocardial infarction. Unstable angina.
Prevention of stroke and transient cerebrovascular accident.
Prevention of thromboembolic complications after surgery or invasive studies 100-300 mg per day.
Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches 100-200 mg per day or 300 mg every other day.

one enteric coated tablet contains
Active ingredient : acetylsalicylic acid 50 mg,
Excipients : corn starch, lactose, microcrystalline cellulose, Plasdon K-90, calcium stearate, Tween-80, collikut MAE 100 R, Plasdon S-630, propylene , talc, castor oil, titanium dioxide.

• Hypersensitivity to ASA, to excipients of the drug and other NSAIDs;

• Erosive and ulcerative lesions of the gastrointestinal tract; gastrointestinal bleeding;

• Bronchial asthma induced by the intake of salicylates and NSAIDs; Fernand-Vidal triad (combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and ASA intolerance);

• Hemorrhagic diathesis;

• Combined use with methotrexate at a dose of 15 mg per week or more;

• Hepatic / renal impairment;

• Pregnancy (I and III trimester) and lactation period;

• Age under 18.

Use with caution: for gout; hyperuricemia; a history of: ulcerative lesions of the gastrointestinal tract or gastrointestinal bleeding; renal and hepatic failure, bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, allergic reactions to other drugs; in the second trimester of pregnancy; in combination with methotrexate at a dose of less than 15 mg per week; deficiency of vitamin K and glucose-6-phosphate dehydrogenase.

Trade name of the drug : CardiASKЃ

International Non-Proprietary Name (INN) : Acetylsalicylic Acid

Dosage form : enteric-coated tablets

Composition : one enteric-coated tablet contains
Active ingredient : acetylsalicylic acid 50 mg, 100 mg;
Excipients : corn starch, lactose, microcrystalline cellulose, plasdon K-90, calcium stearate, tween-80, collikut MAE 100 R, plasdon S-630, propylene glycol, talc, castor oil, titanium dioxide.

Description : enteric-coated tablets, white, round, biconvex. The surface of the tablet is smooth, shiny. Slight roughness is allowed.

Pharmacotherapeutic group : non-steroidal anti-inflammatory drug (NSAID)
ATX code N02BA01

Pharmacological properties
Pharmacodynamics
The mechanism of action of acetylsalicylic acid (ASA) is based on irreversible inhibition of cyclooxygenase (COX-1), as a result of which the synthesis of thromboxane A2 is blocked and platelet aggregation is suppressed. It is believed that ASA has other mechanisms for suppressing platelet aggregation, which expands the scope of its application in various vascular diseases. ASA also has anti-inflammatory, analgesic, antipyretic effects.

Pharmacokinetics
After taking the drug inside, acetylsalicylic acid is absorbed in the upper part of the small intestine. The maximum plasma concentration is observed on average 3 hours after ingestion of the drug. Acetylsalicylic acid undergoes partial metabolism in the liver with the formation of less active metabolites. It is excreted by the kidneys, both unchanged and in the form of metabolites: the half-life for acetylsalicylic acid is about 15 minutes, for metabolites - about 3 hours.

Indications for use

• Prevention of acute myocardial infarction in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) and repeated myocardial infarction;

• Unstable angina

• Prevention of stroke (including in patients with transient cerebrovascular accident);

• Prevention of transient disorders of cerebral circulation;

• Prevention of thromboembolism after surgery and invasive interventions on the vessels (for example, coronary artery bypass grafting, endarterectomy of the carotid arteries, arteriovenous bypass grafting, angioplasty of the carotid arteries);

• Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (for example, with prolonged immobilization as a result of major surgery).

Contraindications

• Hypersensitivity to ASA, to excipients of the drug and other NSAIDs;

• Erosive and ulcerative lesions of the gastrointestinal tract; gastrointestinal bleeding;

• Bronchial asthma induced by the intake of salicylates and NSAIDs; Fernand-Vidal triad (combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and ASA intolerance);

• Hemorrhagic diathesis;

• Combined use with methotrexate at a dose of 15 mg per week or more;

• Hepatic / renal impairment;

• Pregnancy (I and III trimester) and lactation period;

• Age under 18.

Use with caution: for gout; hyperuricemia; a history of: ulcerative lesions of the gastrointestinal tract or gastrointestinal bleeding; renal and hepatic failure, bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, allergic reactions to other drugs; in the second trimester of pregnancy; in combination with methotrexate at a dose of less than 15 mg per week; deficiency of vitamin K and glucose-6-phosphate dehydrogenase.

Use in pregnancy
The use of large doses of salicylates in the first 3 months of pregnancy is associated with an increased incidence of fetal defects (cleft palate, heart defects). In the second trimester of pregnancy, salicylates can be prescribed only with a rigorous assessment of the risks and benefits.
In the last trimester of pregnancy, salicylates in a high dose (more than 300 mg / day) cause a weakening of labor, premature closure of the ductus arteriosus in the fetus, increased bleeding in the mother and fetus, and administration just before childbirth can cause intracranial hemorrhage. especially in premature babies. The appointment of salicylates in the last trimester of pregnancy is contraindicated.

Application during lactation
Salicylates and their metabolites in small amounts pass into breast milk. Accidental intake of salicylates during lactation is not accompanied by the development of adverse reactions in the child and does not require termination of breastfeeding. However, with long-term use of the drug or the appointment of a high dose, breastfeeding should be stopped immediately.

Method of administration and dosage
CardiASK should be taken orally, before meals, with plenty of liquid.
CardiASK is intended for long-term use. The duration of therapy is determined by the attending physician.
Prophylaxis for suspected acute myocardial infarction 100-200 mg / day or 300 mg every other day (the first tablet must be chewed for faster absorption).
Prevention of new-onset acute myocardial infarction in the presence of risk factors 100 mg per day or 300 mg every other day.
Prevention of recurrent myocardial infarction. Unstable angina.
Prevention of stroke and transient cerebrovascular accident.
Prevention of thromboembolic complications after surgery or invasive studies 100-300 mg per day.
Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches 100-200 mg per day or 300 mg every other day.

Side effect
Allergic reactions : urticaria, Quincke's edema.
From the digestive tract : nausea, heartburn, vomiting, pain in the abdomen, ulcers of the mucous membrane of the stomach and duodenum, including perforation, gastrointestinal bleeding, increased activity of 'liver' enzymes.
From the respiratory system : bronchospasm.
From the immune system : anaphylactic reactions.
From the hematopoietic system : anemia (rarely), increased bleeding.
From the side of the central nervous system : dizziness, tinnitus.

Overdose
Symptoms of moderate overdose
Nausea, vomiting, tinnitus, hearing impairment, dizziness, confusion.
Treatment : dose reduction.
Severe overdose symptoms
Fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia.
Treatment: immediate hospitalization in specialized departments for emergency therapy - gastric lavage. determination of acid-base state, alkaline and forced alkaline diuresis, hemodialysis, administration of solutions, activated carbon, symptomatic therapy. When carrying out alkaline diuresis, it is necessary to achieve pH values ??between 7.5 and 8. Forced alkaline diuresis should be carried out when the concentration of salicylates in the blood plasma is more than 500 mg / l (3.6 mmol / l) in adults and 300 mg / l (2 , 2 mmol / l) in children.

Interaction with other drugs
With the simultaneous use of acetylsalicylic acid enhances the effect of the following drugs:

• Methotrescata by reducing renal clearance and displacing it from the connection with proteins;

• Heparin and indirect anticoagulants due to dysfunction of platelets and displacement of indirect anticoagulants from the connection with proteins;

• Thrombotic and antiplatelet drugs (ticlopidine);

• Digoxin due to a decrease in its renal excretion;

• Antidiabetic drugs (insulin and sulfonylurea derivatives) due to the hypoglycemic properties of ASA itself in high doses and the displacement of sulfonylurea derivatives from the connection with proteins;

• Valproic acid by displacing it from the bond with proteins.

An additive effect is observed with the simultaneous administration of ASA with alcohol. ASA weakens the action of uricosuric drugs (benzbromarone) due to competitive tubular elimination of uric acid.
Enhancing the elimination of salicylates, systemic glucocorticosteroids (GCS) weaken their effect.

Special instructions
The drug should be used after a doctor's prescription.
ASA can provoke bronchospasm, as well as cause attacks of bronchial asthma and other hypersensitivity reactions. Risk factors include a history of bronchial asthma, hay fever, nasal polyposis, chronic respiratory diseases, and allergic reactions to other drugs (eg, skin reactions, itching, urticaria).
ASA can cause bleeding of varying severity during and after surgery.
The combination of ASA with anticoagulants, thrombolytics and antiplatelet drugs is accompanied by an increased risk of bleeding.
ASA in low doses can provoke the development of gout in susceptible individuals (with reduced excretion of uric acid).
The combination of ASA with methotrexate is accompanied by an increased incidence of side effects from the hematopoietic organs.
High doses of ASA have a hypoglycemic effect, which must be borne in mind when prescribing it to patients with diabetes mellitus receiving hypoglycemic drugs.
With the combined appointment of GCS and salicylates, it should be remembered that during treatment, the level of salicylates in the blood is reduced, and after the abolition of GCS, an overdose of salicylates is possible.
The combination of ASA with ibuprofen is not recommended, since the latter impairs the beneficial effect of ASA on life expectancy.
Exceeding the dose of ASA is associated with the risk of gastrointestinal bleeding.
Overdose is especially dangerous in elderly patients.
When ASA is combined with alcohol, the risk of damage to the mucous membrane of the gastrointestinal tract and lengthening of bleeding time is increased.

Release form
Enteric-coated tablets, 50 mg and 100 mg.
On 10 or 30 tablets in a blister strip packaging from a film of polyvinyl chloride and printed aluminum foil varnished. 1, 2, 3 blister packs of 10 or 30 tablets, together with instructions for use, are placed in a cardboard box.

Storage conditions
In a dry, dark place at a temperature not exceeding 25 ? C.
Keep out of the reach of children.

Shelf life is
2 years. Do not use the drug after the expiration date printed on the package.

Vacation conditions
Without a doctor's prescription.

Produced by
CJSC 'Canonpharma production'.
Address: Shchelkovo, Moscow region, st. Zarechnaya, 105.